The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers

Frontiers in Bioscience - Landmark

Volumn 19, Issue 4, 2014, Pages 605-618

  Paul, Arindam ^a   Paul, Soumen ^a  

^a UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

BRCA1; BRCA2; Breast cancer; Ovarian cancer; Review

Indexed keywords

BREAST TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; OVARY TUMOR; REVIEW; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; OVARIAN NEOPLASMS;

EID: 84896976197     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4230     Document Type: Review

References (191)

1. M. E. Moynahan, J. W. Chiu, B. H. Koller and M. Jasin: Brca1 controls homology-directed DNA repair. Mol Cell, 4(4), 511-8 (1999)
2. M. E. Moynahan, A. J. Pierce and M. Jasin: BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell, 7(2), 263-72 (2001)
3. K. J. Patel, V. P. Yu, H. Lee, A. Corcoran, F. C. Thistlethwaite, M. J. Evans, W. H. Colledge, L. S. Friedman, B. A. Ponder and A. R. Venkitaraman: Involvement of Brca2 in DNA repair. Mol Cell, 1(3), 347-57 (1998)
4. R. Scully, J. Chen, A. Plug, Y. Xiao, D. Weaver, J. Feunteun, T. Ashley and D. M. Livingston: Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell, 88(2), 265-75 (1997)
5. S. K. Sharan, M. Morimatsu, U. Albrecht, D. S. Lim, E. Regel, C. Dinh, A. Sands, G. Eichele, P. Hasty and A. Bradley: Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature, 386(6627), 804-10 (1997)
6. T. I. Orban and E. Olah: Emerging roles of BRCA1 alternative splicing. Mol Pathol, 56(4), 191-7 (2003)
7. P. Kerr and A. Ashworth: New complexities for BRCA1 and BRCA2. Curr Biol, 11(16), R668-76 (2001)
8. P. L. Welcsh and M. C. King: BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet, 10(7), 705-13 (2001)
9. R. P. Zweemer, P. J. van Diest, R. H. Verheijen, A. Ryan, J. J. Gille, R. H. Sijmons, I. J. Jacobs, F. H. Menko and P. Kenemans: Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol, 76(1), 45-50 (2000)
10. S. Aziz, G. Kuperstein, B. Rosen, D. Cole, R. Nedelcu, J. McLaughlin and S. A. Narod: A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol, 80(3), 341-5 (2001)
11. D. Thompson and D. F. Easton: Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst, 94(18), 1358-65 (2002)
12. J. A. Douglas, A. M. Levin, K. A. Zuhlke, A. M. Ray, G. R. Johnson, E. M. Lange, D. P. Wood and K. A. Cooney: Common variation in the BRCA1 gene and prostate cancer risk. Cancer Epidemiol Biomarkers Prev, 16(7), 1510-6 (2007)
13. D. J. Gallagher, M. M. Gaudet, P. Pal, T. Kirchhoff, L. Balistreri, K. Vora, J. Bhatia, Z. Stadler, S. W. Fine, V. Reuter, M. Zelefsky, M. J. Morris, H. I. Scher, R. J. Klein, L. Norton, J. A. Eastham, P. T. Scardino, M. E. Robson and K. Offit: Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res, 16(7), 2115-21 (2010)
14. S. R. Stecklein, R. A. Jensen and A. Pal: Genetic and epigenetic signatures of breast cancer subtypes. Front Biosci (Elite Ed), 4, 934-49 (2012)
15. K. D. Mirchandani and A. D. D'Andrea: The Fanconi anemia/BRCA pathway: a coordinator of cross-link repair. Exp Cell Res, 312(14), 2647-53 (2006)
16. A. D. D'Andrea and M. Grompe: The Fanconi anaemia/BRCA pathway. Nat Rev Cancer, 3(1), 23-34 (2003)
17. Y. Miki, J. Swensen, D. Shattuck-Eidens, P. A. Futreal, K. Harshman, S. Tavtigian, Q. Liu, C. Cochran, L. M. Bennett, W. Ding and et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266(5182), 66-71 (1994)
18. J. M. Hall, M. K. Lee, B. Newman, J. E. Morrow, L. A. Anderson, B. Huey and M. C. King: Linkage of early-onset familial breast cancer to chromosome 17q21. Science, 250(4988), 1684-9 (1990)
19. P. A. Futreal, Q. Liu, D. Shattuck-Eidens, C. Cochran, K. Harshman, S. Tavtigian, L. M. Bennett, A. Haugen-Strano, J. Swensen, Y. Miki and et al.: BRCA1 mutations in primary breast and ovarian carcinomas. Science, 266(5182), 120-2 (1994)
20. C. X. Deng and F. Scott: Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene, 19(8), 1059-64 (2000) doi:10.1038/sj.onc.1203269
21. C. X. Deng and S. G. Brodie: Roles of BRCA1 and its interacting proteins. Bioessays, 22(8), 728-37 (2000)
22. A. Bhattacharyya, U. S. Ear, B. H. Koller, R. R. Weichselbaum and D. K. Bishop: The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem, 275(31), 23899-903 (2000)
23. S. L. Clark, A. M. Rodriguez, R. R. Snyder, G. D. Hankins and D. Boehning: Structure-Function Of The Tumor Suppressor BRCA1. Comput Struct Biotechnol J, 1(1) (2012)
24. P. S. Brzovic, P. Rajagopal, D. W. Hoyt, M. C. King and R. E. Klevit: Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat Struct Biol, 8(10), 833-7 (2001)
25. J. P. Henderson, J. Byun, M. V. Williams, D. M. Mueller, M. L. McCormick and J. W. Heinecke: Production of brominating intermediates by myeloperoxidase. A transhalogenation pathway for generating mutagenic nucleobases during inflammation. J Biol Chem, 276(11), 7867-75 (2001)
26. R. S. Williams, M. S. Lee, D. D. Hau and J. N. Glover: Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1. Nat Struct Mol Biol, 11(6), 519-25 (2004)
27. S. J. Campbell, R. A. Edwards and J. N. Glover: Comparison of the structures and peptide binding specificities of the BRCT domains of MDC1 and BRCA1. Structure, 18(2), 167-76 (2010)
28. N. Coquelle, R. Green and J. N. Glover: Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition. Biochemistry, 50(21), 4579-89 (2011)
29. L. C. Wu, Z. W. Wang, J. T. Tsan, M. A. Spillman, A. Phung, X. L. Xu, M. C. Yang, L. Y. Hwang, A. M. Bowcock and R. Baer: Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet, 14(4), 430-40 (1996)
30. J. E. Meza, P. S. Brzovic, M. C. King and R. E. Klevit: Mapping the functional domains of BRCA1. Interaction of the ring finger domains of BRCA1 and BARD1. J Biol Chem, 274(9), 5659-65 (1999)
31. R. Scully, J. Chen, R. L. Ochs, K. Keegan, M. Hoekstra, J. Feunteun and D. M. Livingston: Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell, 90(3), 425-35 (1997)
32. K. L. Lorick, J. P. Jensen, S. Fang, A. M. Ong, S. Hatakeyama and A. M. Weissman: RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci U S A, 96(20), 11364-9 (1999)
33. R. Hashizume, M. Fukuda, I. Maeda, H. Nishikawa, D. Oyake, Y. Yabuki, H. Ogata and T. Ohta: The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem, 276(18), 14537-40 (2001)
34. T. Ludwig, D. L. Chapman, V. E. Papaioannou and A. Efstratiadis: Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev, 11(10), 1226-41 (1997)
35. R. Hakem, J. L. de la Pompa, C. Sirard, R. Mo, M. Woo, A. Hakem, A. Wakeham, J. Potter, A. Reitmair, F. Billia, E. Firpo, C. C. Hui, J. Roberts, J. Rossant and T. W. Mak: The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell, 85(7), 1009-23 (1996)
36. E. E. McCarthy, J. T. Celebi, R. Baer and T. Ludwig: Loss of Bard1, the heterodimeric partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability. Mol Cell Biol, 23(14), 5056-63 (2003)
37. C. Y. Liu, A. Flesken-Nikitin, S. Li, Y. Zeng and W. H. Lee: Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev, 10(14), 1835-43 (1996)
38. C. Ghimenti, E. Sensi, S. Presciuttini, I. M. Brunetti, P. Conte, G. Bevilacqua and M. A. Caligo: Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations. Genes Chromosomes Cancer, 33(3), 235-42 (2002)
39. T. Walsh, S. Casadei, M. K. Lee, C. C. Pennil, A. S. Nord, A. M. Thornton, W. Roeb, K. J. Agnew, S. M. Stray, A. Wickramanayake, B. Norquist, K. P. Pennington, R. L. Garcia, M. C. King and E. M. Swisher: Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A, 108(44), 18032-7 (2011)
40. M. L. Li and R. A. Greenberg: Links between genome integrity and BRCA1 tumor suppression. Trends Biochem Sci, 37(10), 418-24 (2012)
41. F. Al-Mulla, J. M. Bland, D. Serratt, J. Miller, C. Chu and G. T. Taylor: Age-dependent penetrance of different germline mutations in the BRCA1 gene. J Clin Pathol, 62(4), 350-6 (2009)
42. S. Thakur, H. B. Zhang, Y. Peng, H. Le, B. Carroll, T. Ward, J. Yao, L. M. Farid, F. J. Couch, R. B. Wilson and B. L. Weber: Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol Cell Biol, 17(1), 444-52 (1997)
43. C. A. Wilson, M. N. Payton, G. S. Elliott, F. W. Buaas, E. E. Cajulis, D. Grosshans, L. Ramos, D. M. Reese, D. J. Slamon and F. J. Calzone: Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Oncogene, 14(1), 1-16 (1997)
44. C. F. Chen, S. Li, Y. Chen, P. L. Chen, Z. D. Sharp and W. H. Lee: The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor. J Biol Chem, 271(51), 32863-8 (1996)
45. D. H. Mohammad and M. B. Yaffe: 14-3-3 proteins, FHA domains and BRCT domains in the DNA damage response. DNA Repair (Amst), 8(9), 1009-17 (2009)
46. Y. L. Chai, J. Cui, N. Shao, E. Shyam, P. Reddy and V. N. Rao: The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter. Oncogene, 18(1), 263-8 (1999)
47. X. Yu, C. C. Chini, M. He, G. Mer and J. Chen: The BRCT domain is a phospho-protein binding domain. Science, 302(5645), 639-42 (2003)
48. X. Yu and J. Chen: DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. Mol Cell Biol, 24(21), 9478-86 (2004)
49. H. Kim, J. Huang and J. Chen: CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage response. Nat Struct Mol Biol, 14(8), 710-5 (2007)
50. M. Schwab, P. Y. Jayet, Y. Allemann, C. Sartori and U. Scherrer: [High altitude pulmonary edema. An experiment of nature to study the underlying mechanisms of hypoxic pulmonary hypertension and pulmonary edema in humans]. Medicina (B Aires), 67(1), 71-81 (2007)
51. L. H. Castilla, F. J. Couch, M. R. Erdos, K. F. Hoskins, K. Calzone, J. E. Garber, J. Boyd, M. B. Lubin, M. L. Deshano, L. C. Brody and et al. : Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet, 8(4), 387-91 (1994)
52. J. A. Clapperton, I. A. Manke, D. M. Lowery, T. Ho, L. F. Haire, M. B. Yaffe and S. J. Smerdon: Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol, 11(6), 512-8 (2004)
53. K. Yamane, E. Katayama and T. Tsuruo: The BRCT regions of tumor suppressor BRCA1 and of XRCC1 show DNA end binding activity with a multimerizing feature. Biochem Biophys Res Commun, 279(2), 678-84 (2000)
54. Y. Chen, C. F. Chen, D. J. Riley, D. C. Allred, P. L. Chen, D. Von Hoff, C. K. Osborne and W. H. Lee: Aberrant subcellular localization of BRCA1 in breast cancer. Science, 270(5237), 789-91 (1995)
55. R. Scully, S. Ganesan, M. Brown, J. A. De Caprio, S. A. Cannistra, J. Feunteun, S. Schnitt and D. M. Livingston: Location of BRCA1 in human breast and ovarian cancer cells. Science, 272(5258), 123-6 (1996)
56. H. Ruffner and I. M. Verma: BRCA1 is a cell cycle-regulated nuclear phosphoprotein. Proc Natl Acad Sci U S A, 94(14), 7138-43 (1997)
57. R. A. Jensen, M. E. Thompson, T. L. Jetton, C. I. Szabo, R. van der Meer, B. Helou, S. R. Tronick, D. L. Page, M. C. King and J. T. Holt: BRCA1 is secreted and exhibits properties of a granin. Nat Genet, 12(3), 303-8 (1996)
58. J. T. Holt, M. E. Thompson, C. Szabo, C. Robinson-Benion, C. L. Arteaga, M. C. King and R. A. Jensen: Growth retardation and tumour inhibition by BRCA1. Nat Genet, 12(3), 298-302 (1996)
59. D. J. Sanz, A. Acedo, M. Infante, M. Duran, L. Perez-Cabornero, E. Esteban-Cardenosa, E. Lastra, F. Pagani, C. Miner and E. A. Velasco: A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients. Clin Cancer Res, 16(6), 1957-67 (2010)
60. M. Lixia, C. Zhijian, S. Chao, G. Chaojiang and Z. Congyi: Alternative splicing of breast cancer associated gene BRCA1 from breast cancer cell line. J Biochem Mol Biol, 40(1), 15-21 (2007)
61. C. F. Xu, M. A. Brown, J. A. Chambers, B. Griffiths, H. Nicolai and E. Solomon: Distinct transcription start sites generate two forms of BRCA1 mRNA. Hum Mol Genet, 4(12), 2259-64 (1995)
62. W. M. ElShamy and D. M. Livingston: Identification of BRCA1-IRIS, a BRCA1 locus product. Nat Cell Biol, 6(10), 954-67 (2004)
63. J. Fortin, A. M. Moisan, M. Dumont, G. Leblanc, Y. Labrie, F. Durocher, P. Bessette, P. Bridge, J. Chiquette, R. Laframboise, J. Lepine, B. Lesperance, R. Pichette, M. Plante, L. Provencher, P. Voyer and J. Simard: A new alternative splice variant of BRCA1 containing an additional in-frame exon. Biochim Biophys Acta, 1731(1), 57-65 (2005)
64. J. Sevcik, M. Falk, P. Kleiblova, F. Lhota, L. Stefancikova, M. Janatova, L. Weiterova, E. Lukasova, S. Kozubek, P. Pohlreich and Z. Kleibl: The BRCA1 alternative splicing variant Delta14-15 with an in-frame deletion of part of the regulatory serine-containing domain (SCD) impairs the DNA repair capacity in MCF-7 cells. Cell Signal, 24(5), 1023-30 (2012)
65. M. Jasin: Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene, 21(58), 8981-93 (2002)
66. S. Ganesan, D. P. Silver, R. A. Greenberg, D. Avni, R. Drapkin, A. Miron, S. C. Mok, V. Randrianarison, S. Brodie, J. Salstrom, T. P. Rasmussen, A. Klimke, C. Marrese, Y. Marahrens, C. X. Deng, J. Feunteun and D. M. Livingston: BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell, 111(3), 393-405 (2002)
67. Y. Chen, A. A. Farmer, C. F. Chen, D. C. Jones, P. L. Chen and W. H. Lee: BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res, 56(14), 3168-72 (1996)
68. A. D. Choudhury, H. Xu and R. Baer: Ubiquitination and proteasomal degradation of the BRCA1 tumor suppressor is regulated during cell cycle progression. J Biol Chem, 279(32), 33909-18 (2004)
69. J. S. Lee, K. M. Collins, A. L. Brown, C. H. Lee and J. H. Chung: hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature, 404(6774), 201-4 (2000)
70. R. S. Tibbetts, D. Cortez, K. M. Brumbaugh, R. Scully, D. Livingston, S. J. Elledge and R. T. Abraham: Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev, 14(23), 2989-3002 (2000)
71. D. Cortez, Y. Wang, J. Qin and S. J. Elledge: Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science, 286(5442), 1162-6 (1999)
72. M. Fabbro, J. A. Rodriguez, R. Baer and B. R. Henderson: BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export. J Biol Chem, 277(24), 21315-24 (2002)
73. L. J. Huber, T. W. Yang, C. J. Sarkisian, S. R. Master, C. X. Deng and L. A. Chodosh: Impaired DNA damage response in cells expressing an exon 11-deleted murine Brca1 variant that localizes to nuclear foci. Mol Cell Biol, 21(12), 4005-15 (2001)
74. J. A. Rodriguez and B. R. Henderson: Identification of a functional nuclear export sequence in BRCA1. J Biol Chem, 275(49), 38589-96 (2000)
75. K. M. Brodie and B. R. Henderson: Characterization of BRCA1 protein targeting, dynamics, and function at the centrosome: a role for the nuclear export signal, CRM1, and Aurora A kinase. J Biol Chem, 287(10), 7701-16 (2012)
76. M. E. Thompson, C. L. Robinson-Benion and J. T. Holt: An amino-terminal motif functions as a second nuclear export sequence in BRCA1. J Biol Chem, 280(23), 21854-7 (2005)
77. S. Li, C. Y. Ku, A. A. Farmer, Y. S. Cong, C. F. Chen and W. H. Lee: Identification of a novel cytoplasmic protein that specifically binds to nuclear localization signal motifs. J Biol Chem, 273(11), 6183-9 (1998)
78. A. J. Fulcher, D. M. Roth, S. Fatima, G. Alvisi and D. A. Jans: The BRCA-1 binding protein BRAP2 is a novel, negative regulator of nuclear import of viral proteins, dependent on phosphorylation flanking the nuclear localization signal. FASEB J, 24(5), 1454-66 (2010)
79. W. L. Lingle, W. H. Lutz, J. N. Ingle, N. J. Maihle and J. L. Salisbury: Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. Proc Natl Acad Sci U S A, 95(6), 2950-5 (1998)
80. L. C. Hsu and R. L. White: BRCA1 is associated with the centrosome during mitosis. Proc Natl Acad Sci U S A, 95(22), 12983-8 (1998)
81. S. Sankaran, L. M. Starita, A. M. Simons and J. D. Parvin: Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function. Cancer Res, 66(8), 4100-7 (2006)
82. L. M. Starita, Y. Machida, S. Sankaran, J. E. Elias, K. Griffin, B. P. Schlegel, S. P. Gygi and J. D. Parvin: BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. Mol Cell Biol, 24(19), 8457-66 (2004)
83. V. Joukov, A. C. Groen, T. Prokhorova, R. Gerson, E. White, A. Rodriguez, J. C. Walter and D. M. Livingston: The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell, 127(3), 539-52 (2006)
84. R. H. Wang, H. Yu and C. X. Deng: A requirement for breast-cancer- associated gene 1 (BRCA1) in the spindle checkpoint. Proc Natl Acad Sci U S A, 101(49), 17108-13 (2004)
85. K. Sato, R. Hayami, W. Wu, T. Nishikawa, H. Nishikawa, Y. Okuda, H. Ogata, M. Fukuda and T. Ohta: Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase. J Biol Chem, 279(30), 30919-22 (2004)
86. W. Wang, A. Budhu, M. Forgues and X. W. Wang: Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol, 7(8), 823-30 (2005)
87. C. Laulier, A. Barascu, J. Guirouilh-Barbat, G. Pennarun, C. Le Chalony, F. Chevalier, G. Palierne, P. Bertrand, J. M. Verbavatz and B. S. Lopez: Bcl-2 inhibits nuclear homologous recombination by localizing BRCA1 to the endomembranes. Cancer Res, 71(10), 3590-602 (2011)
88. I. Plo, C. Laulier, L. Gauthier, F. Lebrun, F. Calvo and B. S. Lopez: AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51. Cancer Res, 68(22), 9404-12 (2008)
89. R. Scully, S. Ganesan, K. Vlasakova, J. Chen, M. Socolovsky and D. M. Livingston: Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell, 4(6), 1093-9 (1999)
90. A. R. Hartman and J. M. Ford: BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat Genet, 32(1), 180-4 (2002)
91. B. Xu, S. Kim and M. B. Kastan: Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol, 21(10), 3445-50 (2001)
92. B. Xu, A. H. O'Donnell, S. T. Kim and M. B. Kastan: Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Cancer Res, 62(16), 4588-91 (2002)
93. A. Husain, G. He, E. S. Venkatraman and D. R. Spriggs: BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res, 58(6), 1120-3 (1998)
94. D. P. Silver, A. L. Richardson, A. C. Eklund, Z. C. Wang, Z. Szallasi, Q. Li, N. Juul, C. O. Leong, D. Calogrias, A. Buraimoh, A. Fatima, R. S. Gelman, P. D. Ryan, N. M. Tung, A. De Nicolo, S. Ganesan, A. Miron, C. Colin, D. C. Sgroi, L. W. Ellisen, E. P. Winer and J. E. Garber: Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol, 28(7), 1145-53 (2010)
95. D. W. Abbott, M. E. Thompson, C. Robinson-Benion, G. Tomlinson, R. A. Jensen and J. T. Holt: BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem, 274(26), 18808-12 (1999)
96. K. A. Scata and W. S. El-Deiry: p53, BRCA1 and breast Cancer chemoresistance. Adv Exp Med Biol, 608, 70-86 (2007)
97. R. I. Yarden, S. Pardo-Reoyo, M. Sgagias, K. H. Cowan and L. C. Brody: BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet, 30(3), 285-9 (2002)
98. J. Zhang and S. N. Powell: The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res, 3(10), 531-9 (2005)
99. Y. Wang, D. Cortez, P. Yazdi, N. Neff, S. J. Elledge and J. Qin: BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev, 14(8), 927-39 (2000)
100. A. Traven and J. Heierhorst: SQ/TQ cluster domains: concentrated ATM/ATR kinase phosphorylation site regions in DNA-damage-response proteins. Bioessays, 27(4), 397-407 (2005)
101. M. Gatei, B. B. Zhou, K. Hobson, S. Scott, D. Young and K. K. Khanna: Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brca1 at distinct and overlapping sites. In vivo assessment using phospho-specific antibodies. J Biol Chem, 276(20), 17276-80 (2001)
102. J. Chen: Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage. Cancer Res, 60(18), 5037-9 (2000)
103. Q. Zhong, C. F. Chen, S. Li, Y. Chen, C. C. Wang, J. Xiao, P. L. Chen, Z. D. Sharp and W. H. Lee: Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science, 285(5428), 747-50 (1999)
104. S. M. Sy, M. S. Huen and J. Chen: PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci U S A, 106(17), 7155-60 (2009)
105. E. D. Coene, M. S. Hollinshead, A. A. Waeytens, V. R. Schelfhout, W. P. Eechaute, M. K. Shaw, P. M. Van Oostveldt and D. J. Vaux: Phosphorylated BRCA1 is predominantly located in the nucleus and mitochondria. Mol Biol Cell, 16(2), 997-1010 (2005)
106. V. Tembe and B. R. Henderson: BARD1 translocation to mitochondria correlates with Bax oligomerization, loss of mitochondrial membrane potential, and apoptosis. J Biol Chem, 282(28), 20513-22 (2007)
107. K. M. Brodie and B. R. Henderson: Differential modulation of BRCA1 and BARD1 nuclear localisation and foci assembly by DNA damage. Cell Signal, 22(2), 291-302 (2010)
108. M. E. Thompson, R. A. Jensen, P. S. Obermiller, D. L. Page and J. T. Holt: Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet, 9(4), 444-50 (1995) doi:10.1038/ng0495-444
109. P. De Luca, E. S. Vazquez, C. P. Moiola, F. Zalazar, J. Cotignola, G. Gueron, K. Gardner and A. De Siervi: BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer. Mol Cancer Res, 9(8), 1078-90 (2011)
110. O. N. Aprelikova, B. S. Fang, E. G. Meissner, S. Cotter, M. Campbell, A. Kuthiala, M. Bessho, R. A. Jensen and E. T. Liu: BRCA1-associated growth arrest is RB-dependent. Proc Natl Acad Sci U S A, 96(21), 11866-71 (1999)
111. M. Classon and E. Harlow: The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer, 2(12), 910-7 (2002)
112. K. I. Zeller, X. Zhao, C. W. Lee, K. P. Chiu, F. Yao, J. T. Yustein, H. S. Ooi, Y. L. Orlov, A. Shahab, H. C. Yong, Y. Fu, Z. Weng, V. A. Kuznetsov, W. K. Sung, Y. Ruan, C. V. Dang and C. L. Wei: Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A, 103(47), 17834-9 (2006)
113. Q. Wang, H. Zhang, K. Kajino and M. I. Greene: BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene, 17(15), 1939-48 (1998)
114. M. A. Pujana, J. D. Han, L. M. Starita, K. N. Stevens, M. Tewari, J. S. Ahn, G. Rennert, V. Moreno, T. Kirchhoff, B. Gold, V. Assmann, W. M. Elshamy, J. F. Rual, D. Levine, L. S. Rozek, R. S. Gelman, K. C. Gunsalus, R. A. Greenberg, B. Sobhian, N. Bertin, K. Venkatesan, N. Ayivi-Guedehoussou, X. Sole, P. Hernandez, C. Lazaro, K. L. Nathanson, B. L. Weber, M. E. Cusick, D. E. Hill, K. Offit, D. M. Livingston, S. B. Gruber, J. D. Parvin and M. Vidal: Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet, 39(11), 1338-49 (2007)
115. C. A. Maxwell, J. Benitez, L. Gomez-Baldo, A. Osorio, N. Bonifaci, R. Fernandez-Ramires, S. V. Costes, E. Guino, H. Chen, G. J. Evans, P. Mohan, I. Catala, A. Petit, H. Aguilar, A. Villanueva, A. Aytes, J. Serra-Musach, G. Rennert, F. Lejbkowicz, P. Peterlongo, S. Manoukian, B. Peissel, C. B. Ripamonti, B. Bonanni, A. Viel, A. Allavena, L. Bernard, P. Radice, E. Friedman, B. Kaufman, Y. Laitman, M. Dubrovsky, R. Milgrom, A. Jakubowska, C. Cybulski, B. Gorski, K. Jaworska, K. Durda, G. Sukiennicki, J. Lubinski, Y. Y. Shugart, S. M. Domchek, R. Letrero, B. L. Weber, F. B. Hogervorst, M. A. Rookus, J. M. Collee, P. Devilee, M. J. Ligtenberg, R. B. Luijt, C. M. Aalfs, Q. Waisfisz, J. Wijnen, C. E. Roozendaal, D. F. Easton, S. Peock, M. Cook, C. Oliver, D. Frost, P. Harrington, D. G. Evans, F. Lalloo, R. Eeles, L. Izatt, C. Chu, D. Eccles, F. Douglas, C. Brewer, H. Nevanlinna, T. Heikkinen, F. J. Couch, N. M. Lindor, X. Wang, A. K. Godwin, M. A. Caligo, G. Lombardi, N. Loman, P. Karlsson, H. Ehrencrona, A. Wachenfeldt, R. B. Barkardottir, U. Hamann, M. U. Rashid, A. Lasa, T. Caldes, R. Andres, M. Schmitt, V. Assmann, K. Stevens, K. Offit, J. Curado, H. Tilgner, R. Guigo, G. Aiza, J. Brunet, J. Castellsague, G. Martrat, A. Urruticoechea, I. Blanco, L. Tihomirova, D. E. Goldgar, S. Buys, E. M. John, A. Miron, M. Southey, M. B. Daly, R. K. Schmutzler, B. Wappenschmidt, A. Meindl, N. Arnold, H. Deissler, R. Varon-Mateeva, C. Sutter, D. Niederacher, E. Imyamitov, O. M. Sinilnikova, D. Stoppa-Lyonne, S. Mazoyer, C. Verny-Pierre, L. Castera, A. de Pauw, Y. J. Bignon, N. Uhrhammer, J. P. Peyrat, P. Vennin, S. Fert Ferrer, M. A. Collonge-Rame, I. Mortemousque, A. B. Spurdle, J. Beesley, X. Chen, S. Healey, M. H. Barcellos-Hoff, M. Vidal, S. B. Gruber, C. Lazaro, G. Capella, L. McGuffog, K. L. Nathanson, A. C. Antoniou, G. Chenevix-Trench, M. C. Fleisch, V. Moreno and M. A. Pujana: Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol, 9(11), e1001199 (2011)
116. H. Zhang, K. Somasundaram, Y. Peng, H. Tian, D. Bi, B. L. Weber and W. S. El-Deiry: BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene, 16(13), 1713-21 (1998)
117. L. Zheng, L. A. Annab, C. A. Afshari, W. H. Lee and T. G. Boyer: BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci U S A, 98(17), 9587-92 (2001)
118. T. Ouchi, S. W. Lee, M. Ouchi, S. A. Aaronson and C. M. Horvath: Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes. Proc Natl Acad Sci U S A, 97(10), 5208-13 (2000)
119. A. K. Wong, P. A. Ormonde, R. Pero, Y. Chen, L. Lian, G. Salada, S. Berry, Q. Lawrence, P. Dayananth, P. Ha, S. V. Tavtigian, D. H. Teng and P. L. Bartel: Characterization of a carboxy-terminal BRCA1 interacting protein. Oncogene, 17(18), 2279-85 (1998)
120. X. Yu, L. C. Wu, A. M. Bowcock, A. Aronheim and R. Baer: The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J Biol Chem, 273(39), 25388-92 (1998)
121. L. Zheng, H. Pan, S. Li, A. Flesken-Nikitin, P. L. Chen, T. G. Boyer and W. H. Lee: Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. Mol Cell, 6(4), 757-68 (2000)
122. S. F. Anderson, B. P. Schlegel, T. Nakajima, E. S. Wolpin and J. D. Parvin: BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat Genet, 19(3), 254-6 (1998)
123. R. Scully, S. F. Anderson, D. M. Chao, W. Wei, L. Ye, R. A. Young, D. M. Livingston and J. D. Parvin: BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci U S A, 94(11), 5605-10 (1997)
124. A. De Siervi, P. De Luca, J. S. Byun, L. J. Di, T. Fufa, C. M. Haggerty, E. Vazquez, C. Moiola, D. L. Longo and K. Gardner: Transcriptional autoregulation by BRCA1. Cancer Res, 70(2), 532-42 (2010)
125. L. J. Di, A. G. Fernandez, A. De Siervi, D. L. Longo and K. Gardner: Transcriptional regulation of BRCA1 expression by a metabolic switch. Nat Struct Mol Biol, 17(12), 1406-13 (2010)
126. G. C. Chen, L. S. Guan, J. H. Yu, G. C. Li, H. R. Choi Kim and Z. Y. Wang: Rb-associated protein 46 (RbAp46) inhibits transcriptional transactivation mediated by BRCA1. Biochem Biophys Res Commun, 284(2), 507-14 (2001)
127. D. A. Bochar, L. Wang, H. Beniya, A. Kinev, Y. Xue, W. S. Lane, W. Wang, F. Kashanchi and R. Shiekhattar: BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell, 102(2), 257-65 (2000)
128. S. Furuta, J. M. Wang, S. Wei, Y. M. Jeng, X. Jiang, B. Gu, P. L. Chen, E. Y. Lee and W. H. Lee: Removal of BRCA1/CtIP/ZBRK1 repressor complex on ANG1 promoter leads to accelerated mammary tumor growth contributed by prominent vasculature. Cancer Cell, 10(1), 13-24 (2006)
129. P. B. Mullan, J. E. Quinn and D. P. Harkin: The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene, 25(43), 5854-63 (2006)
130. R. Wooster, S. L. Neuhausen, J. Mangion, Y. Quirk, D. Ford, N. Collins, K. Nguyen, S. Seal, T. Tran, D. Averill and et al.: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science, 265(5181), 2088-90 (1994)
131. P. Bork, N. Blomberg and M. Nilges: Internal repeats in the BRCA2 protein sequence. Nat Genet, 13(1), 22-3 (1996)
132. P. L. Chen, C. F. Chen, Y. Chen, J. Xiao, Z. D. Sharp and W. H. Lee: The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A, 95(9), 5287-92 (1998)
133. A. K. Wong, R. Pero, P. A. Ormonde, S. V. Tavtigian and P. L. Bartel: RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem, 272(51), 31941-4 (1997)
134. L. Pellegrini, D. S. Yu, T. Lo, S. Anand, M. Lee, T. L. Blundell and A. R. Venkitaraman: Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature, 420(6913), 287-93 (2002)
135. J. Chen, D. P. Silver, D. Walpita, S. B. Cantor, A. F. Gazdar, G. Tomlinson, F. J. Couch, B. L. Weber, T. Ashley, D. M. Livingston and R. Scully: Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell, 2(3), 317-28 (1998)
136. B. H. Spain, C. J. Larson, L. S. Shihabuddin, F. H. Gage and I. M. Verma: Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations. Proc Natl Acad Sci U S A, 96(24), 13920-5 (1999)
137. O. Preobrazhenska, M. Yakymovych, T. Kanamoto, I. Yakymovych, R. Stoika, C. H. Heldin and S. Souchelnytskyi: BRCA2 and Smad3 synergize in regulation of gene transcription. Oncogene, 21(36), 5660-4 (2002)
138. S. Shin and I. M. Verma: BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription. Proc Natl Acad Sci U S A, 100(12), 7201-6 (2003)
139. H. Yang, P. D. Jeffrey, J. Miller, E. Kinnucan, Y. Sun, N. H. Thoma, N. Zheng, P. L. Chen, W. H. Lee and N. P. Pavletich: BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science, 297(5588), 1837-48 (2002)
140. F. Connor, D. Bertwistle, P. J. Mee, G. M. Ross, S. Swift, E. Grigorieva, V. L. Tybulewicz and A. Ashworth: Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat Genet, 17(4), 423-30 (1997)
141. P. L. Tavormina, R. Shiang, L. M. Thompson, Y. Z. Zhu, D. J. Wilkin, R. S. Lachman, W. R. Wilcox, D. L. Rimoin, D. H. Cohn and J. J. Wasmuth: Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet, 9(3), 321-8 (1995)
142. S. Miyakis, G. Sourvinos and D. A. Spandidos: Differential expression and mutation of the ras family genes in human breast cancer. Biochem Biophys Res Commun, 251(2), 609-12 (1998)
143. M. C. King, J. H. Marks and J. B. Mandell: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302(5645), 643-6 (2003)
144. A. Antoniou, P. D. Pharoah, S. Narod, H. A. Risch, J. E. Eyfjord, J. L. Hopper, N. Loman, H. Olsson, O. Johannsson, A. Borg, B. Pasini, P. Radice, S. Manoukian, D. M. Eccles, N. Tang, E. Olah, H. Anton-Culver, E. Warner, J. Lubinski, J. Gronwald, B. Gorski, H. Tulinius, S. Thorlacius, H. Eerola, H. Nevanlinna, K. Syrjakoski, O. P. Kallioniemi, D. Thompson, C. Evans, J. Peto, F. Lalloo, D. G. Evans and D. F. Easton: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet, 72(5), 1117-30 (2003)
145. D. M. van der Kolk, G. H. de Bock, B. K. Leegte, M. Schaapveld, M. J. Mourits, J. de Vries, A. H. van der Hout and J. C. Oosterwijk: Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat, 124(3), 643-51 (2010)
146. A. Veronesi, C. de Giacomi, M. D. Magri, D. Lombardi, M. Zanetti, C. Scuderi, R. Dolcetti, A. Viel, D. Crivellari, E. Bidoli and M. Boiocchi: Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases. BMC Cancer, 5, 70 (2005)
147. T. Debniak, R. J. Scott, B. Gorski, C. Cybulski, T. van de Wetering, P. Serrano-Fernandez, T. Huzarski, T. Byrski, L. Nagay, B. Debniak, E. Kowalska, A. Jakubowska, J. Gronwald, D. Wokolorczyk, R. Maleszka, J. Kladny and J. Lubinski: Common variants of DNA repair genes and malignant melanoma. Eur J Cancer, 44(1), 110-4 (2008)
148. L. Kadouri, A. Hubert, Y. Rotenberg, T. Hamburger, M. Sagi, C. Nechushtan, D. Abeliovich and T. Peretz: Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet, 44(7), 467-71 (2007)
149. C. Cybulski, B. Gorski, J. Gronwald, T. Huzarski, T. Byrski, T. Debniak, A. Jakubowska, D. Wokolorczyk, B. Gliniewicz, A. Sikorski, M. Stawicka, D. Godlewski, Z. Kwias, A. Antczak, K. Krajka, W. Lauer, M. Sosnowski, P. Sikorska-Radek, K. Bar, R. Klijer, Z. Romuald, B. Malkiewicz, A. Borkowski, T. Borkowski, M. Szwiec, M. Posmyk, S. A. Narod and J. Lubinski: BRCA1 mutations and prostate cancer in Poland. Eur J Cancer Prev, 17(1), 62-6 (2008)
150. J. Suchy, C. Cybulski, B. Gorski, T. Huzarski, T. Byrski, T. Debniak, J. Gronwald, A. Jakubowska, D. Wokolorczyk, G. Kurzawski, J. Kladny, A. Jawien, Z. Banaszkiewicz, R. Wisniowski, P. Wandzel, J. Starzewski, Z. Lorenc, E. Korobowicz, P. Krokowicz, K. Horbacka, J. Lubinski and S. A. Narod: BRCA1 mutations and colorectal cancer in Poland. Fam Cancer, 9(4), 541-4 (2010)
151. D. P. Atchley, C. T. Albarracin, A. Lopez, V. Valero, C. I. Amos, A. M. Gonzalez-Angulo, G. N. Hortobagyi and B. K. Arun: Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol, 26(26), 4282-8 (2008)
152. N. Tung, Y. Wang, L. C. Collins, J. Kaplan, H. Li, R. Gelman, A. H. Comander, B. Gallagher, K. Fetten, K. Krag, K. A. Stoeckert, R. D. Legare, D. Sgroi, P. D. Ryan, J. E. Garber and S. J. Schnitt: Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res, 12(1), R12 (2010)
153. N. Tung, A. Miron, S. J. Schnitt, S. Gautam, K. Fetten, J. Kaplan, Y. Yassin, A. Buraimoh, J. Y. Kim, A. M. Szasz, R. Tian, Z. C. Wang, L. C. Collins, J. Brock, K. Krag, R. D. Legare, D. Sgroi, P. D. Ryan, D. P. Silver, J. E. Garber and A. L. Richardson: Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res, 12(6), R95 (2010)
154. J. Boyd, Y. Sonoda, M. G. Federici, F. Bogomolniy, E. Rhei, D. L. Maresco, P. E. Saigo, L. A. Almadrones, R. R. Barakat, C. L. Brown, D. S. Chi, J. P. Curtin, E. A. Poynor and W. J. Hoskins: Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA, 283(17), 2260-5 (2000)
155. W. D. Foulkes: Re: Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst, 95(17), 1344; author reply 1344 (2003)
156. S. R. Lakhani, J. S. Reis-Filho, L. Fulford, F. Penault-Llorca, M. van der Vijver, S. Parry, T. Bishop, J. Benitez, C. Rivas, Y. J. Bignon, J. Chang-Claude, U. Hamann, C. J. Cornelisse, P. Devilee, M. W. Beckmann, C. Nestle-Kramling, P. A. Daly, N. Haites, J. Varley, F. Lalloo, G. Evans, C. Maugard, H. Meijers-Heijboer, J. G. Klijn, E. Olah, B. A. Gusterson, S. Pilotti, P. Radice, S. Scherneck, H. Sobol, J. Jacquemier, T. Wagner, J. Peto, M. R. Stratton, L. McGuffog and D. F. Easton: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res, 11(14), 5175-80 (2005)
157. T. Sorlie, R. Tibshirani, J. Parker, T. Hastie, J. S. Marron, A. Nobel, S. Deng, H. Johnsen, R. Pesich, S. Geisler, J. Demeter, C. M. Perou, P. E. Lonning, P. O. Brown, A. L. Borresen-Dale and D. Botstein: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A, 100(14), 8418-23 (2003)
158. O. T. Johannsson, I. Idvall, C. Anderson, A. Borg, R. B. Barkardottir, V. Egilsson and H. Olsson: Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer, 33(3), 362-71 (1997)
159. N. Loman, O. Johannsson, P. O. Bendahl, A. Borg, M. Ferno and H. Olsson: Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer, 83(2), 310-9 (1998)
160. A. Musolino, M. A. Bella, B. Bortesi, M. Michiara, N. Naldi, P. Zanelli, M. Capelletti, D. Pezzuolo, R. Camisa, M. Savi, T. M. Neri and A. Ardizzoni: BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. Breast, 16(3), 280-92 (2007)
161. N. C. Turner, J. S. Reis-Filho, A. M. Russell, R. J. Springall, K. Ryder, D. Steele, K. Savage, C. E. Gillett, F. C. Schmitt, A. Ashworth and A. N. Tutt: BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene, 26(14), 2126-32 (2007)
162. A. Catteau, W. H. Harris, C. F. Xu and E. Solomon: Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene, 18(11), 1957-65 (1999)
163. O. Bougie and J. I. Weberpals: Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review. Int J Surg Oncol, 2011, 374012 (2011)
164. M. B. Daly, J. E. Axilbund, S. Buys, B. Crawford, C. D. Farrell, S. Friedman, J. E. Garber, S. Goorha, S. B. Gruber, H. Hampel, V. Kaklamani, W. Kohlmann, A. Kurian, J. Litton, P. K. Marcom, R. Nussbaum, K. Offit, T. Pal, B. Pasche, R. Pilarski, G. Reiser, K. M. Shannon, J. R. Smith, E. Swisher and J. N. Weitzel: Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw, 8(5), 562-94 (2010)
165. T. B. Bevers, D. K. Armstrong, B. Arun, R. W. Carlson, K. H. Cowan, M. B. Daly, I. Fleming, J. E. Garber, M. Gemignani, W. J. Gradishar, H. Krontiras, S. Kulkarni, C. Laronga, L. Loftus, D. J. Macdonald, M. C. Mahoney, S. D. Merajver, I. Meszoely, L. Newman, E. Pritchard, V. Seewaldt, R. V. Sellin, C. L. Shapiro and J. H. Ward: Breast cancer risk reduction. J Natl Compr Canc Netw, 8(10), 1112-46 (2010)
166. S. Iodice, M. Barile, N. Rotmensz, I. Feroce, B. Bonanni, P. Radice, L. Bernard, P. Maisonneuve and S. Gandini: Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer, 46(12), 2275-84 (2010)
167. S. M. Domchek, T. M. Friebel, C. F. Singer, D. G. Evans, H. T. Lynch, C. Isaacs, J. E. Garber, S. L. Neuhausen, E. Matloff, R. Eeles, G. Pichert, L. Van t'veer, N. Tung, J. N. Weitzel, F. J. Couch, W. S. Rubinstein, P. A. Ganz, M. B. Daly, O. I. Olopade, G. Tomlinson, J. Schildkraut, J. L. Blum and T. R. Rebbeck: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA, 304(9), 967-75 (2010)
168. B. Evers, T. Helleday and J. Jonkers: Targeting homologous recombination repair defects in cancer. Trends Pharmacol Sci, 31(8), 372-80 (2010)
169. T. Helleday, E. Petermann, C. Lundin, B. Hodgson and R. A. Sharma: DNA repair pathways as targets for cancer therapy. Nat Rev Cancer, 8(3), 193-204 (2008)
170. H. E. Bryant, N. Schultz, H. D. Thomas, K. M. Parker, D. Flower, E. Lopez, S. Kyle, M. Meuth, N. J. Curtin and T. Helleday: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 434(7035), 913-7 (2005)
171. H. Farmer, N. McCabe, C. J. Lord, A. N. Tutt, D. A. Johnson, T. B. Richardson, M. Santarosa, K. J. Dillon, I. Hickson, C. Knights, N. M. Martin, S. P. Jackson, G. C. Smith and A. Ashworth: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434(7035), 917-21 (2005)
172. N. McCabe, N. C. Turner, C. J. Lord, K. Kluzek, A. Bialkowska, S. Swift, S. Giavara, M. J. O'Connor, A. N. Tutt, M. Z. Zdzienicka, G. C. Smith and A. Ashworth: Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res, 66(16), 8109-15 (2006)
173. S. A. Martin, C. J. Lord and A. Ashworth: DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev, 18(1), 80-6 (2008)
174. C. K. Anders, E. P. Winer, J. M. Ford, R. Dent, D. P. Silver, G. W. Sledge and L. A. Carey: Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res, 16(19), 4702-10 (2010)
175. A. Tutt, M. Robson, J. E. Garber, S. M. Domchek, M. W. Audeh, J. N. Weitzel, M. Friedlander, B. Arun, N. Loman, R. K. Schmutzler, A. Wardley, G. Mitchell, H. Earl, M. Wickens and J. Carmichael: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet, 376(9737), 235-44 (2010)
176. P. C. Fong, D. S. Boss, T. A. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, P. Mortimer, H. Swaisland, A. Lau, M. J. O'Connor, A. Ashworth, J. Carmichael, S. B. Kaye, J. H. Schellens and J. S. de Bono: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med, 361(2), 123-34 (2009)
177. S. R. Stecklein, E. Kumaraswamy, F. Behbod, W. Wang, V. Chaguturu, L. M. Harlan-Williams and R. A. Jensen: BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation. Proc Natl Acad Sci U S A, 109(34), 13650-5 (2012)
178. R. Agarwal and S. B. Kaye: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer, 3(7), 502-16 (2003)
179. I. Cass, R. L. Baldwin, T. Varkey, R. Moslehi, S. A. Narod and B. Y. Karlan: Improved survival in women with BRCA-associated ovarian carcinoma. Cancer, 97(9), 2187-95 (2003)
180. A. Chetrit, G. Hirsh-Yechezkel, Y. Ben-David, F. Lubin, E. Friedman and S. Sadetzki: Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol, 26(1), 20-5 (2008)
181. W. Sakai, E. M. Swisher, B. Y. Karlan, M. K. Agarwal, J. Higgins, C. Friedman, E. Villegas, C. Jacquemont, D. J. Farrugia, F. J. Couch, N. Urban and T. Taniguchi: Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature, 451(7182), 1116-20 (2008)
182. E. M. Swisher, W. Sakai, B. Y. Karlan, K. Wurz, N. Urban and T. Taniguchi: Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res, 68(8), 2581-6 (2008)
183. W. Sakai, E. M. Swisher, C. Jacquemont, K. V. Chandramohan, F. J. Couch, S. P. Langdon, K. Wurz, J. Higgins, E. Villegas and T. Taniguchi: Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res, 69(16), 6381-6 (2009)
184. S. L. Edwards, R. Brough, C. J. Lord, R. Natrajan, R. Vatcheva, D. A. Levine, J. Boyd, J. S. Reis-Filho and A. Ashworth: Resistance to therapy caused by intragenic deletion in BRCA2. Nature, 451(7182), 1111-5 (2008)
185. K. K. Dhillon, E. M. Swisher and T. Taniguchi: Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci, 102(4), 663-9 (2011)
186. C. A. Rabik and M. E. Dolan: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev, 33(1), 9-23 (2007)
187. M. McVey and S. E. Lee: MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. Trends Genet, 24(11), 529-38 (2008)
188. K. Xie, J. Doles, M. T. Hemann and G. C. Walker: Error-prone translesion synthesis mediates acquired chemoresistance. Proc Natl Acad Sci U S A, 107(48), 20792-7 (2010)
189. C. Jacquemont and T. Taniguchi: Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res, 67(15), 7395-405 (2007)
190. A. J. Deans, K. K. Khanna, C. J. McNees, C. Mercurio, J. Heierhorst and G. A. McArthur: Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. Cancer Res, 66(16), 8219-26 (2006)
191. F. A. Dungey, K. W. Caldecott and A. J. Chalmers: Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol Cancer Ther, 8(8), 2243-54 (2009)